DK1183020T3 - (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes - Google Patents
(3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetesInfo
- Publication number
- DK1183020T3 DK1183020T3 DK00938074T DK00938074T DK1183020T3 DK 1183020 T3 DK1183020 T3 DK 1183020T3 DK 00938074 T DK00938074 T DK 00938074T DK 00938074 T DK00938074 T DK 00938074T DK 1183020 T3 DK1183020 T3 DK 1183020T3
- Authority
- DK
- Denmark
- Prior art keywords
- trihalomethylphenoxy
- halophenyl
- diabetes
- treatment
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/325,997 US6262118B1 (en) | 1999-06-04 | 1999-06-04 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1183020T3 true DK1183020T3 (da) | 2006-11-27 |
Family
ID=23270381
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05076901.7T DK1614418T3 (da) | 1999-06-04 | 2000-06-02 | Anvendelse af (-)(3-trihalomethylphenoxy)(4-halophenyl)eddikesyrederivater til behandling af hyperurikæmi |
DK00938074T DK1183020T3 (da) | 1999-06-04 | 2000-06-02 | (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05076901.7T DK1614418T3 (da) | 1999-06-04 | 2000-06-02 | Anvendelse af (-)(3-trihalomethylphenoxy)(4-halophenyl)eddikesyrederivater til behandling af hyperurikæmi |
Country Status (32)
Country | Link |
---|---|
US (6) | US6262118B1 (da) |
EP (2) | EP1183020B1 (da) |
JP (2) | JP4685300B2 (da) |
KR (2) | KR100779787B1 (da) |
CN (2) | CN100379412C (da) |
AR (1) | AR042574A1 (da) |
AT (2) | ATE524173T1 (da) |
AU (1) | AU775909C (da) |
BR (1) | BR0011342A (da) |
CA (2) | CA2751187C (da) |
CL (1) | CL2011001971A1 (da) |
CO (1) | CO5170453A1 (da) |
CY (1) | CY1112861T1 (da) |
CZ (1) | CZ20014341A3 (da) |
DE (1) | DE60030109T2 (da) |
DK (2) | DK1614418T3 (da) |
ES (2) | ES2371476T3 (da) |
HK (2) | HK1087616A1 (da) |
HU (1) | HUP0201611A3 (da) |
IL (3) | IL146914A0 (da) |
MX (1) | MXPA01012435A (da) |
NO (1) | NO20015909L (da) |
NZ (2) | NZ528266A (da) |
PE (1) | PE20010220A1 (da) |
PT (2) | PT1614418E (da) |
RU (2) | RU2281762C2 (da) |
SA (1) | SA00210535B1 (da) |
SK (1) | SK17562001A3 (da) |
TW (1) | TWI264303B (da) |
UA (1) | UA74147C2 (da) |
WO (1) | WO2000074666A2 (da) |
ZA (3) | ZA200300888B (da) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624194B1 (en) * | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
US20080108825A1 (en) * | 1999-11-08 | 2008-05-08 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
US20080103302A1 (en) * | 2000-02-04 | 2008-05-01 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
NZ521806A (en) * | 2000-04-12 | 2004-07-30 | Puracyp | Compositions and methods for induction of proteins involved in xenobiotic metabolism |
AR030379A1 (es) * | 2000-08-22 | 2003-08-20 | Novartis Ag | Combinaciones |
CA2437118A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
DE60326232D1 (de) * | 2002-06-03 | 2009-04-02 | Novartis Ag | Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie |
JP2005531606A (ja) * | 2002-06-10 | 2005-10-20 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ステロール製剤およびステロールの組合せ |
CA2529774C (en) * | 2003-06-20 | 2014-05-27 | Metabolex, Inc. | Resolution of .alpha.-(phenoxy)phenylacetic acid derivatives |
CN100525757C (zh) * | 2003-06-20 | 2009-08-12 | 麦它波莱克斯股份有限公司 | α-(苯氧基)苯乙酸衍生物的拆分 |
US7199259B2 (en) * | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
JP2007525497A (ja) * | 2004-02-18 | 2007-09-06 | メタボレックス インコーポレーティッド | 抗糖尿病薬としてのアルファ−(トリフルオロメチル置換アリールオキシ、アリールアミノ、アリールチオまたはアリールメチル)−トリフルオロメチル置換フェニル酢酸および誘導体 |
BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
CN1997633A (zh) * | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的***及其制备方法 |
WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
US8288438B2 (en) * | 2005-03-21 | 2012-10-16 | Metabolex, Inc. | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer |
EA200702274A1 (ru) | 2005-04-20 | 2008-04-28 | Метаболекс, Инк. | Твёрдые кристаллические и аморфные формы (-)-галофената и способ их получения, фармацевтическая композиция на их основе и способ лечения |
JPWO2007007757A1 (ja) * | 2005-07-12 | 2009-01-29 | 第一三共株式会社 | PPARγアゴニストを含有する医薬組成物 |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
US7432394B2 (en) * | 2005-09-23 | 2008-10-07 | Metabolex, Inc. | Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines |
US7714131B2 (en) * | 2005-09-23 | 2010-05-11 | Metabolex, Inc. | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof |
WO2007114315A1 (ja) * | 2006-03-30 | 2007-10-11 | Santen Pharmaceutical Co., Ltd. | 角結膜障害治療剤 |
US8212083B2 (en) * | 2006-04-27 | 2012-07-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
KR100788454B1 (ko) * | 2006-06-15 | 2007-12-24 | 대원제약주식회사 | 속효성이 증진된 나테글리니드를 유효성분으로 함유하는약제학적 조성물 |
WO2008028914A1 (en) | 2006-09-07 | 2008-03-13 | Nycomed Gmbh | Combination treatment for diabetes mellitus |
WO2009052182A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
EP2152663B1 (en) | 2007-06-04 | 2014-03-19 | Ben Gurion University of the Negev Research and Development Authority | Tri-aryl compounds and compositions comprising the same |
EP2167681B1 (en) * | 2007-07-03 | 2013-01-16 | Joslin Diabetes Center, Inc. | Treatment of cardiovascular disease with salicylates |
WO2009046371A1 (en) * | 2007-10-05 | 2009-04-09 | Metabolex, Inc. | Methods of treating metabolic diseases |
WO2009121940A1 (en) * | 2008-04-03 | 2009-10-08 | Janssen Pharmaceutica Nv | Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
SG11201402032RA (en) * | 2011-11-04 | 2014-09-26 | Metabolex Inc | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
US9023856B2 (en) | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
WO2013066352A1 (en) * | 2011-11-04 | 2013-05-10 | Metabolex, Inc. | Methods for treating gout in patient subpopulations |
SG11201401981TA (en) * | 2011-11-04 | 2014-05-29 | Metabolex Inc | Methods for treating gout flares |
CA2870014A1 (en) * | 2012-04-13 | 2013-10-17 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
EP2847152A4 (en) * | 2012-05-10 | 2016-03-23 | Cellix Bio Private Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
EP2852570B1 (en) | 2012-05-23 | 2020-04-22 | Cellixbio Private Limited | Composition for the treatment of inflammatory bowel disease |
CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
EA201690938A1 (ru) | 2013-11-05 | 2016-11-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
DK3242869T3 (da) | 2015-01-06 | 2022-01-31 | Cellix Bio Private Ltd | Sammensætninger og fremgangsmåder til behanding af inflammation og smerte |
JP6192142B2 (ja) * | 2016-09-13 | 2017-09-06 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | 痛風発赤の治療方法 |
JP6368756B2 (ja) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
CN109369471A (zh) * | 2018-12-10 | 2019-02-22 | 石家庄度恩医药科技有限公司 | 一种光学活性R-4-氯-α-(3-三氟甲基苯氧基)苯乙酸的制备方法 |
WO2021236394A1 (en) | 2020-05-18 | 2021-11-25 | Cymabay Therapeutics, Inc. | Cb-0406 tromethamine salt |
WO2021236395A1 (en) | 2020-05-18 | 2021-11-25 | Cymabay Therapeutics, Inc. | Cb-0406 choline salt |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3378582A (en) * | 1964-03-20 | 1968-04-16 | Merck & Co Inc | (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids |
US3517051A (en) * | 1964-03-20 | 1970-06-23 | Merck & Co Inc | Phenoxy substituted phenylacetic acids |
US3517050A (en) | 1966-10-03 | 1970-06-23 | Merck & Co Inc | Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid |
NL6712585A (da) | 1966-10-03 | 1968-04-04 | ||
DK133742B (da) | 1970-10-30 | 1976-07-12 | Merck & Co Inc | Fremgangsmåde til fremstilling af 2-acetamidoethyl-(3-trifluormethylphenoxy)-(4-chlorphenyl)-acetat. |
US3923855A (en) | 1972-07-13 | 1975-12-02 | Merck & Co Inc | 2-sulfonyloxyethyl 3-trifluoromethylphenoxy-4{40 -chlorophenyl acetate |
US3860628A (en) * | 1972-07-13 | 1975-01-14 | Merck & Co Inc | Cyanomethyl(3-trifluoromethylphenoxy)(4-chlorophenyl)acetate |
NL7309039A (da) * | 1972-07-13 | 1974-01-15 | ||
US3953490A (en) | 1972-07-13 | 1976-04-27 | Merck & Co., Inc. | Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile |
NL7309571A (da) | 1972-07-28 | 1974-01-30 | ||
US4110351A (en) | 1973-04-02 | 1978-08-29 | Richardson-Merrell Inc. | Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts |
IL48707A0 (en) | 1974-12-30 | 1976-02-29 | Synthelabo | Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4532135A (en) * | 1981-02-09 | 1985-07-30 | Edwards K David G | Renoprotective treatments employing vasodilator compounds |
DE3525284A1 (de) * | 1985-07-16 | 1987-01-29 | Boehringer Mannheim Gmbh | Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten |
US5028052A (en) * | 1990-05-11 | 1991-07-02 | Miller Omer E | Golf mat |
DE4111026A1 (de) | 1991-04-05 | 1992-10-08 | Boehringer Mannheim Gmbh | Optisch aktive carbonsaeuren sowie diese enthaltende arzneimittel |
US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
JPH0927811A (ja) * | 1995-07-13 | 1997-01-28 | Fujitsu Ltd | 輻輳監視制御装置 |
WO1997010813A1 (en) | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5716987A (en) * | 1996-06-21 | 1998-02-10 | Bristol-Myers Squibb Company | Prophylactic and therapeutic treatment of skin sensitization and irritation |
US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6624194B1 (en) * | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
US6576662B2 (en) | 2000-05-05 | 2003-06-10 | Dr. Reddy's Laboratories Limited | Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them |
US6693094B2 (en) | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
WO2004000790A1 (en) | 2002-06-20 | 2003-12-31 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
WO2004078113A2 (en) * | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
US7199259B2 (en) * | 2003-06-20 | 2007-04-03 | Metabolex, Inc. | Resolution of α-(phenoxy)phenylacetic acid derivatives |
CA2529774C (en) | 2003-06-20 | 2014-05-27 | Metabolex, Inc. | Resolution of .alpha.-(phenoxy)phenylacetic acid derivatives |
EP1729597B1 (en) | 2004-03-16 | 2011-03-09 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome |
WO2007102861A2 (en) | 2005-12-02 | 2007-09-13 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
US7635710B2 (en) | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
-
1999
- 1999-06-04 US US09/325,997 patent/US6262118B1/en not_active Expired - Lifetime
-
2000
- 2000-02-06 UA UA2001129087A patent/UA74147C2/uk unknown
- 2000-06-02 JP JP2001501203A patent/JP4685300B2/ja not_active Expired - Fee Related
- 2000-06-02 NZ NZ528266A patent/NZ528266A/en unknown
- 2000-06-02 KR KR1020067022082A patent/KR100779787B1/ko not_active IP Right Cessation
- 2000-06-02 US US09/585,907 patent/US6613802B1/en not_active Expired - Lifetime
- 2000-06-02 ZA ZA200300888A patent/ZA200300888B/xx unknown
- 2000-06-02 AT AT05076901T patent/ATE524173T1/de active
- 2000-06-02 HU HU0201611A patent/HUP0201611A3/hu active IP Right Revival
- 2000-06-02 CN CNB2004100116574A patent/CN100379412C/zh not_active Expired - Fee Related
- 2000-06-02 AT AT00938074T patent/ATE336235T1/de active
- 2000-06-02 EP EP00938074A patent/EP1183020B1/en not_active Expired - Lifetime
- 2000-06-02 WO PCT/US2000/015235 patent/WO2000074666A2/en active Application Filing
- 2000-06-02 IL IL14691400A patent/IL146914A0/xx unknown
- 2000-06-02 EP EP05076901A patent/EP1614418B1/en not_active Expired - Lifetime
- 2000-06-02 CZ CZ20014341A patent/CZ20014341A3/cs unknown
- 2000-06-02 PE PE2000000551A patent/PE20010220A1/es not_active Application Discontinuation
- 2000-06-02 PT PT05076901T patent/PT1614418E/pt unknown
- 2000-06-02 CA CA2751187A patent/CA2751187C/en not_active Expired - Fee Related
- 2000-06-02 ES ES05076901T patent/ES2371476T3/es not_active Expired - Lifetime
- 2000-06-02 SK SK1756-2001A patent/SK17562001A3/sk unknown
- 2000-06-02 ES ES00938074T patent/ES2269151T3/es not_active Expired - Lifetime
- 2000-06-02 DE DE60030109T patent/DE60030109T2/de not_active Expired - Lifetime
- 2000-06-02 CN CNB008112908A patent/CN1189168C/zh not_active Expired - Fee Related
- 2000-06-02 PT PT00938074T patent/PT1183020E/pt unknown
- 2000-06-02 CA CA2371723A patent/CA2371723C/en not_active Expired - Fee Related
- 2000-06-02 BR BR0011342-5A patent/BR0011342A/pt not_active Application Discontinuation
- 2000-06-02 ZA ZA200300889A patent/ZA200300889B/xx unknown
- 2000-06-02 DK DK05076901.7T patent/DK1614418T3/da active
- 2000-06-02 RU RU2002100037/04A patent/RU2281762C2/ru not_active IP Right Cessation
- 2000-06-02 NZ NZ515902A patent/NZ515902A/xx unknown
- 2000-06-02 MX MXPA01012435A patent/MXPA01012435A/es active IP Right Grant
- 2000-06-02 DK DK00938074T patent/DK1183020T3/da active
- 2000-06-02 AR ARP000102742A patent/AR042574A1/es unknown
- 2000-06-02 KR KR1020017015625A patent/KR100721219B1/ko not_active IP Right Cessation
- 2000-06-02 AU AU53162/00A patent/AU775909C/en not_active Ceased
- 2000-06-03 TW TW089110927A patent/TWI264303B/zh not_active IP Right Cessation
- 2000-06-06 CO CO00041901A patent/CO5170453A1/es not_active Application Discontinuation
- 2000-10-31 US US09/703,487 patent/US6646004B1/en not_active Expired - Lifetime
- 2000-11-15 SA SA00210535A patent/SA00210535B1/ar unknown
-
2001
- 2001-12-03 NO NO20015909A patent/NO20015909L/no not_active Application Discontinuation
- 2001-12-04 IL IL146914A patent/IL146914A/en not_active IP Right Cessation
- 2001-12-04 ZA ZA200109973A patent/ZA200109973B/en unknown
-
2002
- 2002-09-06 HK HK06107787.6A patent/HK1087616A1/xx not_active IP Right Cessation
- 2002-09-06 HK HK02106591.8A patent/HK1045111B/zh not_active IP Right Cessation
-
2003
- 2003-09-10 US US10/660,112 patent/US20050075396A1/en not_active Abandoned
-
2005
- 2005-10-18 RU RU2005132222/15A patent/RU2005132222A/ru not_active Application Discontinuation
-
2007
- 2007-01-23 JP JP2007013175A patent/JP4685808B2/ja not_active Expired - Fee Related
- 2007-03-22 US US11/690,026 patent/US20070270490A1/en not_active Abandoned
- 2007-11-25 IL IL187605A patent/IL187605A/en not_active IP Right Cessation
-
2009
- 2009-07-16 US US12/504,487 patent/US8354448B2/en not_active Expired - Fee Related
-
2011
- 2011-08-12 CL CL2011001971A patent/CL2011001971A1/es unknown
- 2011-12-12 CY CY20111101227T patent/CY1112861T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1183020T3 (da) | (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes | |
DK1093370T3 (da) | Farmaceutisk præparat til behandling af diabetes | |
DK1196163T3 (da) | Farmaceutiske sammensætninger til behandling af insulinresistens | |
DK0941103T3 (da) | Farmaceutisk præparat til behandling af diabetes | |
DK1223997T3 (da) | Medicinsk infusionssæt | |
DK1174135T3 (da) | Farmaceutisk sammensætning omfattende pioglitazon og glimepirid til anvendelse i behandling af diabetes | |
NO20043733L (no) | Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme | |
DK1329456T3 (da) | Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme | |
DE69907885D1 (de) | Spritze und Spritzenkolben | |
DK1036794T3 (da) | 2-Aryl-8-oxodihydropurinderivater, fremgangsmåde til fremstilling af samme, medicinske præparater indeholdende samme og mellemprodukter deraf | |
DK1180518T3 (da) | 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DK0881495T3 (da) | Kontrol af diabetes | |
DE60011853D1 (de) | Injektionsspritze | |
DE69919784D1 (de) | Spritze | |
NO20022087L (no) | Fremgangsmåte for behandling av diabetes | |
BR9901100B1 (pt) | composiÇço fungicida lÍquida e concentrada. | |
IS5852A (is) | Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum | |
DK1017408T3 (da) | Anvendelse af tetrahydrolipstatin i behandling af diabetes type II | |
DK1001783T3 (da) | Behandling af diabetes med thiazolidindion, insulinsekretagog og biguanid | |
WO2002044113A3 (en) | Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | |
DK1202996T3 (da) | Titanforbindelser, fremstilling og anvendelse heraf | |
AU2003252182A8 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
NO20035056D0 (no) | Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes | |
IS7275A (is) | Samsetning fyrir hollegg og notkun á henni | |
DE60040851D1 (de) | N und einrichtung zu dessen herstellung |